BPC-157 Duration of Action: Why Dosing Schedules Matter

BPC-157 at a glance:

• Drug class: Research peptide (not FDA-approved)
• Route: subcutaneous or oral in research; commonly self-administered as injection by users (not endorsed)
• Typical frequency: studied protocols vary; most published animal work uses daily dosing
• Half-life: approximately 4 hours (oral, in animal models)

The half-life of BPC-157 (approximately 4 hours (oral, in animal models)) is the single most important number for understanding why it's dosed the way it is. Below we unpack the practical implications.

Half-Life Defined

The half-life is the time it takes for the concentration of a drug in the bloodstream to fall by half. It governs how often a drug needs to be dosed to maintain therapeutic levels and how long the drug persists after the last dose.

For BPC-157, the half-life is approximately 4 hours (oral, in animal models). That number explains the studied protocols vary; most published animal work uses daily dosing dosing schedule.

Time to Steady State

After starting (or changing) a dose, drug levels reach a new "steady state" after about 5 half-lives.

For BPC-157: practical steady state takes ~5x the half-life listed above. That's why dose changes don't show their full effect immediately.

How Long BPC-157 Stays in Your System

A common question: "if I stop BPC-157, how long does it stay in my body?"

The standard rule of thumb is that a drug is essentially cleared after 5 half-lives. For BPC-157: that's approximately 20 hours. Effects on appetite, glucose, or other targets persist for a similar period before fully resolving.

For this compound, downstream effects depend on the cellular pathways involved.

Practical Implications

A long half-life:

• Allows less frequent dosing (better adherence)
• Smooths out peaks and troughs (often better tolerability)
• Means dose changes take longer to fully express
• Creates a longer "runway" if a dose is missed

A short half-life:

• Requires more frequent dosing
• Produces sharper concentration peaks (and matching side effects)
• Allows faster dose adjustments
• Provides faster clearance if stopped

BPC-157, with its short half-life, falls on the short end of this spectrum.

Half-Life and Missed Doses

If a dose is missed:

• Take the missed dose as soon as you remember if you're well within the dosing interval
• Skip it if you're closer to the next dose
• Never double up

The longer the half-life, the more forgiving the missed-dose window. For BPC-157, timing matters more.

Half-Life Across the Drug Class

Within the broader class of research peptide (not fda-approved), half-lives vary significantly. Half-life variation across the class affects dosing frequency and tolerability profiles. See our comparison pages for direct comparisons.

Bottom Line

The approximately 4 hours (oral, in animal models) half-life of BPC-157 is what makes its studied protocols vary; most published animal work uses daily dosing schedule work. Shorter half-lives need more frequent dosing; longer ones offer more flexibility.

Frequently Asked Questions

Related Reading

• What Is BPC-157? Everything You Should Know Before Starting
• Is BPC-157 Safe? An Honest Look at the Side-Effect Profile
• BPC-157 Results: What the Real Numbers Show in 2026
• How Much Does BPC-157 Really Cost? The Honest Breakdown
• BPC-157 Cycle and Protocol: What Researchers Actually Use
• How Much BPC-157 Should You Take? A Practical Dosing Guide

Sources

• Goldstein AL et al. Thymosin β4: A Multi-Functional Regenerative Peptide. Annals NY Acad Sci 2012;1269:1.
• Sosne G et al. Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy. Expert Opinion 2015;15:663.
• Sikiric P et al. Stable Gastric Pentadecapeptide BPC 157 — Major Wound-Healing Properties. Pharmaceuticals 2020;13:155.

This page is informational only and is not medical advice.